Dechra Pharmaceuticals (DB:1PK) - Cotización, noticias y análisis

Resumen de acción 1PK

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.

Acerca de la empresa

1PK fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 62.48%

Análisis de riesgos

Los pagos de intereses no están bien cubiertos por los beneficios

Competidores de Dechra Pharmaceuticals PLC

Dermapharm Holding

XTRA:DMP

€1.7b

Bayer

XTRA:BAYN

€26.9b

Merck KGaA

XTRA:MRK

€66.8b

PharmaSGP Holding

XTRA:PSG

€261.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Dechra Pharmaceuticals
Historical stock prices
Current Share Price	UK£44.40
52 Week High	UK£45.20
52 Week Low	UK£28.00
Beta	0.78
1 Month Change	0.45%
3 Month Change	2.30%
1 Year Change	35.37%
3 Year Change	9.25%
5 Year Change	65.18%
Change since IPO	272.64%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	1PK	DE Pharmaceuticals	Mercado DE
7D	-0.4%	2.5%	1.8%
1Y	35.4%	-27.7%	2.2%

Rentabilidad vs. Industria: 1PK superó al sector German Pharmaceuticals , que obtuvo un rendimiento del -31.9% el año pasado.

Rentabilidad vs. Mercado: 1PK superó al mercado German, que obtuvo un rendimiento del -0.3% el año pasado.

Volatilidad de los precios

Is 1PK's price volatile compared to industry and market?
1PK volatility
1PK Average Weekly Movement	2.8%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: 1PK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 1PK (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1997	2,457	Ian Page	www.dechra.com

Resumen de fundamentos de Dechra Pharmaceuticals PLC

¿Cómo se comparan los beneficios e ingresos de Dechra Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de 1PK
Capitalización bursátil	€5.11b
Beneficios(TTM)	-€32.39m
Ingresos (TTM)	€884.12m

5.8x

Ratio precio-ventas (PS)

-157.8x

Ratio precio-beneficio (PE)

¿Está 1PK sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 1PK
Ingresos	UK£761.50m
Coste de los ingresos	UK£331.90m
Beneficio bruto	UK£429.60m
Otros gastos	UK£457.50m
Beneficios	-UK£27.90m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.24
Margen bruto	56.42%
Margen de beneficio neto	-3.66%
Ratio deuda/patrimonio	64.6%

¿Cómo se ha desempeñado 1PK a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 1PK

Recompensas

Análisis de riesgos

Competidores de Dechra Pharmaceuticals PLC

XTRA:DMP

€1.7b

XTRA:BAYN

€26.9b

XTRA:MRK

€66.8b

XTRA:PSG

€261.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Recent updates

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Investor sentiment improves as stock rises 33%

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Now 20% undervalued after recent price drop

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 22% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Now 21% undervalued after recent price drop

Less than half of directors are independent

Non-Executive Chairman recently bought €119k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Upcoming dividend of UK£0.29 per share

Board Member recently sold €1.0m worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold €1.1m worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: €41.36

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: €38.84

CEO, MD & Executive Director recently sold €12m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Upcoming Dividend of UK£0.24 Per Share

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: €38.52

Non-Executive Director recently bought €28k worth of stock

Non-Executive Director recently bought €28k worth of stock

Independent Non Executive Director recently sold €142k worth of stock

Full year earnings released - EPS €0.33

New 90-day high - €36.48

New 90-day high - €33.70

New 90-day high - €32.96

Rentabilidad de los accionistas